NCT05058443View on ClinicalTrials.gov

Denosumab and Osteoporotic Vertebral Compression Fracture

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

January 6, 2020

Primary Completion Date

August 5, 2022

Study Completion Date

August 10, 2022

Conditions
Osteoporotic Vertebral Compression Fracture
Interventions
DRUG

Denosumab 60 mg/ml [Prolia]

denosumab subcutaneously every 6 months (Q6M)

DRUG

Placebo

placebo subcutaneously every 6 months (Q6M)

Trial Locations (1)

518000

ShenzhenPH, Shenzhen

All Listed Sponsors
lead

Shenzhen People's Hospital

OTHER

NCT05058443 - Denosumab and Osteoporotic Vertebral Compression Fracture | Biotech Hunter | Biotech Hunter